← All trials
NCT00824343
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2008
- Primary completion
- Apr 1, 2011
- Completion date
- Jun 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 86
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- PiramalLead sponsor
- Central India Cancer Research Institute, NagpurOverall official - principal investigator
- Bharat HospitalOverall official - principal investigator
- CSM Medical University, LucknowOverall official - principal investigator
- GKNM Hospital, Coimbatore, IndiaOverall official - principal investigator
- Regional Cancer Centre, TrivandramOverall official - principal investigator
- Jaslok Hospital and Research Centre, Mumbai, IndiaOverall official - principal investigator
- Bhagwan Mahaveer Jain HospitalOverall official - principal investigator
- Deenanath Mangeshkar Hospital & Research CentreOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.